dbACP: A Comprehensive Database of Anti-Cancer Peptides

482 result(s) have been found!

Accession Name Sequence Source/Organism Mechanism Assay Type Cell Line Cancer Type Activity
dbacp00032 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10% inhibition at 10-5 M
dbacp00033 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.2% inhibition at 10-4 M
dbacp00034 Enkephalins7 analogue-8 YA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 36.1% inhibition at 10-3 M
dbacp00057 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.5% inhibition at 10-6 M
dbacp00058 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 6.1% inhibition at 10-5 M
dbacp00059 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 3.1% inhibition at 10-4 M
dbacp00060 Enkephalins7 analogue-9 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 14.8% inhibition at 10-3 M
dbacp00082 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.2% inhibition at 10-6 M
dbacp00083 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 17.1% inhibition at 10-5 M
dbacp00084 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-4 M
dbacp00085 Enkephalins7 analogue-10 YSA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 20.5% inhibition at 10-3 M
dbacp00129 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.8% inhibition at 10-6 M
dbacp00130 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 7.3% inhibition at 10-5 M
dbacp00131 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.9% inhibition at 10-4 M
dbacp00132 Enkephalins7 analogue-15 YSA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00163 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.0% inhibition at 10-6 M
dbacp00164 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.7% inhibition at 10-5 M
dbacp00165 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 11.6% inhibition at 10-4 M
dbacp00166 Enkephalins7 analogue-16 YRA*G Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.2% inhibition at 10-3 M
dbacp00196 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 4.9% inhibition at 10-6 M
dbacp00197 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 10.2% inhibition at 10-5 M
dbacp00198 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 13.3% inhibition at 10-4 M
dbacp00199 Enkephalins7 analogue-17 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 28.0% inhibition at 10-3 M
dbacp00230 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 8.5% inhibition at 10-6 M
dbacp00231 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.5% inhibition at 10-5 M
dbacp00232 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 15.4% inhibition at 10-4 M
dbacp00233 Enkephalins7 analogue-18 YA*GFM Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 24.1% inhibition at 10-3 M
dbacp00281 Enkephalins7 analogue-23 YGGFMA* Synthetic Peptide Apoptosis inducing MTT/MTS assay HeLa Cervical cancer 9.3% inhibition at 10-3 M
dbacp00326 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 46.2 ± 7.6 μM
dbacp00331 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.3 ± 0.2 μM
dbacp00336 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 30.8 ± 2.0 μM
dbacp00341 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 36.2 ± 2.8 μM
dbacp00346 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 29.0 ± 3.7 μM
dbacp00351 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 6.4 ± 0.6 μM
dbacp00356 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 33.3 ±7.4 μM
dbacp00361 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 9.5 ± 0.5 μM
dbacp00366 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 51.0 ± 4.6 μM
dbacp00371 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.6 ± 0.2 μM
dbacp00376 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 15.6 ± 3.6 μM
dbacp00381 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00386 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 37.5 ± 3.3 μM
dbacp00391 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.4 ± 0.2 μM
dbacp00396 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 38.5 ± 4.8 μM
dbacp00401 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 15.5 ± 0.8 μM
dbacp00407 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 22.5 ± 3.3 μM
dbacp00412 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 3.0 ± 0.1 μM
dbacp00417 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 14.9 ± 0.8 μM
dbacp00422 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 51.5 ± 3.9 μM
dbacp00427 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.2 μM
dbacp00432 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 14.1 ± 0.9 μM
dbacp00444 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 19.5 ± 0.5 μM
dbacp00449 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 1.7 ± 0.1 μM
dbacp00454 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 9.0 ± 0.5 μM
dbacp00459 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 44.2 ± 2.2 μM
dbacp00464 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 6.7 ± 0.7 μM
dbacp00469 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.1 ± 0.2 μM
dbacp00474 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 9.0 ± 1.1μM
dbacp00479 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 5.1 ± 0.3 μM
dbacp00484 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 26.5 ± 2.4 μM
dbacp00489 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.0 ± 0.1 μM
dbacp00494 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 14.7 ± 1.5 μM
dbacp00499 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 20.9 ± 1.4 μM
dbacp00504 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.2 ± 1.9 μM
dbacp00509 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.3 ± 0.1 μM
dbacp00514 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 15.7 ±1.1μM
dbacp00519 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 10.4 ± 1.0 μM
dbacp00524 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 29.4 ± 1.1 μM
dbacp00529 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.0 ± 0.3 μM
dbacp00534 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 34.5 ± 3.6 μM
dbacp00539 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 39.4 ± 2.6 μM
dbacp00544 [K8R]cGm GCRRLCYRQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.1 ± 0.1 μM
dbacp00549 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 18.3 ± 1.4 μM
dbacp00554 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.0 ± 0.1 μM
dbacp00559 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 25.0 ± 2.9 μM
dbacp00564 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 17.1 ± 0.7 μM
dbacp00569 [L5W]cGm GCRRWCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 1.0 ± 0.1 μM
dbacp00577 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : > 64 μM
dbacp00582 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 10.3 ± 1.1 μM
dbacp00587 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 51.2 ± 4.0 μM
dbacp00592 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00597 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 48.4 ± 0.7 μM
dbacp00602 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 11.5 ± 0.6 μM
dbacp00607 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay HL-60 Cervical cancer CC50 : 34.1 ± 3.9 μM
dbacp00612 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 30.8 ± 2.5 μM
dbacp00625 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 30.3 ± 1.1 μM
dbacp00630 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 4.0 ± 0.1 μM
dbacp00635 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 68.4 ± 9.6 μM
dbacp00640 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 50.4 ± 2.4 μM
dbacp00645 [Y14W]cGm GCRRLCYKQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.7 ± 0.1 μM
dbacp00650 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 31.6 ± 1.3 μM
dbacp00655 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.4 ± 0.3 μM
dbacp00660 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 31.3 ± 2.6 μM
dbacp00665 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 41.0 ± 4.2 μM
dbacp00670 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.1 ± 1.4 μM
dbacp00675 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.1 μM
dbacp00680 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 23.3 ± 0.4 μM
dbacp00685 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 5.1 ± 0.3 μM
dbacp00690 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 39.7 ± 3.8 μM
dbacp00695 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp00700 [Y7W]cGm GCRRLCWKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.9 ± 0.2 μM
dbacp00780 A12L KWKSFLKTFKSLKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.8 µMo/L
dbacp00788 A12L/A20L KWKSFLKTFKSLKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2 µMo/L
dbacp00796 A12L/A20L/A23L KWKSFLKTFKSLKKTVLHTLLKLISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.2 µMo/L
dbacp00804 A20L KWKSFLKTFKSAKKTVLHTLLKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.3 µMo/L
dbacp00815 AAD (or Aa-Pri1) MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYPSDYNGKTVGPDEKIQINSCGRENASSGTEGSFDIVDPNDGNKTIRHFYWECPWGSKRNTWTPSGSNTKWMVEWSGQNLDSGALGTITVDVLRKGN Purified from chestnut mushroom Apoptosis inducing MTT/MTS assay HeLa Cervical cancer At 2.5 µM concentration,decrease in cell vibility: 70%
dbacp01597 BF-30 KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF Banded krait Cytoplasmic membrane permeabilization and DNAspecified-binding Lactate dehydrogenase release assay, DNA retardation assay, Real-time PCR, Western blot, wound healing assay, and chick embryo chorioallantoic membrane assay B16 Human Cervical cancer IC50 : 13.9 μM
dbacp01598 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp01599 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 90-95% viablity
dbacp01600 BF2d TRSSRAGLQWPVGRVHRLLRKGGC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 90-100% viablity
dbacp01892 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 32.5 ± 0.5 μM
dbacp01893 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 29.5 ± 2 μM
dbacp01894 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 46.0 ± 3 μM
dbacp01895 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 50.0 ± 10 μM
dbacp01896 BPC194 KKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 40.0 ± 3 Μm
dbacp01897 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 31.2 ± 5 μM
dbacp01898 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 22.5 ± 0 μM
dbacp01899 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 32.5 ± 4 μM
dbacp01900 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 28.0 ± 3 μM
dbacp01901 BPC88 KKLLKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 32.5 ± 11 μM
dbacp01902 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.0 ± 7 μM
dbacp01903 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 24.5 ± 0.7 μM
dbacp01904 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 34.5 ± 2 μM
dbacp01905 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 35.0 ± 7 μM
dbacp01906 BPC96 LKLKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 51.0 ± 6 Μm
dbacp01907 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay MDA-MB-231 Cervical cancer IC50 : 40.7 ± 3 μM
dbacp01908 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 38.5 ± 4 μM
dbacp01909 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay HepG2 Cervical cancer IC50 : 44.0 ± 3 μM
dbacp01910 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay A431 Cervical cancer IC50 : 47.5 ± 4 μM
dbacp01911 BPC98 LLKKKFKKLQ Synthetic Peptide Inducing apoptosis MTT assay Panc-1 Cervical cancer IC50 : 44.5 ± 0.7 Μm
dbacp02304 Cartilage protein hydrolysate peptide FIMGPY Skate Cell proliferation inhibition; Apoptosis inducing MTT assay HeLa Cervical cancer IC50 : 4.81 mg/mL
dbacp02315 Cationic Amphiphilic GIIKKIIIKKI AMP Membrane disruption WST-1 assay HeLa Cervical cancer IC50 : 160 µM
dbacp02316 Cationic Amphiphilic GIIKKIIIKKIIIKKI AMP Membrane disruption WST-1 assay HeLa Cervical cancer IC50 : 15 µM
dbacp02399 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 39.8 ± 1.0 μM
dbacp02404 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 2.9 ± 0.1 μM
dbacp02409 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 71.7 ± 9.2 μM
dbacp02414 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : > 64 μM
dbacp02419 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay MCF-7 Cervical cancer CC50 : 15.3 ± 1.4 μM
dbacp02424 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 2.7 ± 0.1 μM
dbacp02429 cGm (Derived from Gm) GCRRLCYKQRCVTYCRGR Synthetic construct Target and destroy tumor cell membranes Cell viability assay PBMCs Cervical cancer CC50 : 12.7 ± 1.1 μM
dbacp02581 CSP-FT FTPGGNTYAGQP Not found Cell membrane disintegration Not specified C-33A Human Cervical cancer Not found
dbacp02582 CSP-GD GDALFSVPLEVY Not found Cell membrane disintegration Not specified SiH Human Cervical cancer Not found
dbacp02583 CSP-KQ KQNLAEG Not found Cell membrane disintegration Not specified C-33A Human Cervical cancer Not found
dbacp02584 CSP-SI SIDDQRDVAEFA Not found Cell membrane disintegration Not specified C-33A Human Cervical cancer Not found
dbacp02585 CSP-TL TLHQPPSSANWI Not found Cell membrane disintegration Not specified SiH Human Cervical cancer Not found
dbacp02757 Dimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))2 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.31 nM
dbacp02836 Emericellipsin A PQAAIVASG **Emericellopsis alkaline** VKPM F1428, Alkalophile, extremophile Disrupt cell membrane structures; Apoptosis MTT assay HeLa Cervical cancer EC50 : < 0.5 µM
dbacp02843 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 45% Cytotoxicity at 50 mg/L
dbacp02844 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 38% Cytotoxicity at 25 mg/L
dbacp02845 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75% Cytotoxicity at 50 mg/L
dbacp02846 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 65% Cytotoxicity at 25 mg/L
dbacp02847 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp02848 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 65% Cytotoxicity at 25 mg/L
dbacp02849 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 83% Cytotoxicity at 50 mg/L
dbacp02850 Epinecidin-1 GFIFHIIKGLFHAGKMIHGLV Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 77 % Cytotoxicity at 25 mg/L
dbacp02874 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 60 % Cytotoxicity at 50 mg/L
dbacp02875 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 50 % Cytotoxicity at 25 mg/L
dbacp02876 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 8 % Cytotoxicity at 12.5 mg/L
dbacp02877 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 6.25 mg/L
dbacp02878 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp02879 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp02880 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp02881 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 12.5 mg/L
dbacp02882 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 7 % Cytotoxicity at 6.25 mg/L
dbacp02883 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp02884 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 76 % Cytotoxicity at 50 mg/L
dbacp02885 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp02886 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 12 % Cytotoxicity at 12.5 mg/L
dbacp02887 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 6.25 mg/L
dbacp02888 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 3.125 mg/L
dbacp02889 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp02890 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 25 mg/L
dbacp02891 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 8 % Cytotoxicity at 12.5 mg/L
dbacp02892 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 3 % Cytotoxicity at 6.25 mg/L
dbacp02893 Epinecidin-8 FIFHIIKGLFHAGKMI Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 3 % Cytotoxicity at 3.125 mg/L
dbacp02929 Figainin 1 FIGTLIPLALGALTKLFK Chaco tree frog Membrane disruption and cell lysis MTT/MTS assay NIH/3T3 Cervical cancer IC50 : 13 µM
dbacp02935 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay NIH/3T3 Cervical cancer IC50 : 13 µM
dbacp02938 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay B16F10 Cervical cancer IC50 : 10.5 µM
dbacp02941 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay MCF Cervical cancer IC50 : 13.7 µM
dbacp02944 Figainin 1 MAFLKKSLFLVLFLGLVSLSIGEEEKREEEEKNEEGANQEENAENKEKRFIGTLIPLALGALTKLFKG Chaco tree frog Anti-proliferative action MTT/MTS assay HeLa Cervical cancer IC50 : 11.1 µM
dbacp02945 Figainin 1 FIGTLIPLALGALTKLFK Skin secretions, Chaco tree frog, South America Membrane disruption MTT/MTS assay NIH/3T3 Cervical cancer IC50 : 13 µM
dbacp02961 FIMGPY FIMGPY Not found Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 4.81 mg/mL
dbacp03128 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Fluorescence-based assay using a Fluorescence Imaging Plate Reader HeLa Cervical cancer CC50 : 54.1 ± 5.0 μM
dbacp03133 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Cell viability assay K-562 Cervical cancer CC50 : 3.8 ± 0.3 μM
dbacp03138 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Cell viability assay CRL-1739 Cervical cancer CC50 : 67.0 ± 5.0 μM
dbacp03143 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Cell viability assay MM96L Cervical cancer CC50 : 3.7 ± 0.2 μM
dbacp03148 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Cell viability assay HFF-1 Cervical cancer CC50 : 49.9 ±16.6 μM
dbacp03153 Gomesin ZCRRLCYKQRCVTYCRGR Tarantula spider sp. Target and destroy tumor cell membranes Cell viability assay HeLa Cervical cancer CC50 : 54.1 ± 5.0 μM
dbacp03189 HAL-1 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 11 ± 2 µM
dbacp03192 HAL-1/10 GMWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 2 µM
dbacp03195 HAL-1/12 GKWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 43 ± 14 µM
dbacp03198 HAL-1/15 GMWSKLLGHLLR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03201 HAL-1/17 KMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 35 ± 3 µM
dbacp03204 HAL-1/18 GMWSKILKHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 2 µM
dbacp03207 HAL-1/19 GKWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03210 HAL-1/20 GKWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 22 ± 3 µM
dbacp03213 HAL-1/21 GKWKKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 30 ± 3 µM
dbacp03216 HAL-1/22 gmwskilghlir Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ±3 µM
dbacp03219 HAL-1/29 GMWSKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03222 HAL-1/4 GMWSKILGHLKR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp03225 HAL-1/5 GMWKKILGHLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 1 µM
dbacp03228 HAL-1/6 GMWSKILGHLIK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 1 µM
dbacp03231 HAL-1/9 GMWSKILGKLIR Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 1 µM
dbacp03234 HAL-2 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 1 µM
dbacp03237 HAL-2/1 GKWKSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03240 HAL-2/11 GKWLSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 3 µM
dbacp03243 HAL-2/13 GKWMTLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 3 µM
dbacp03246 HAL-2/18 GKWMSLLKHIWK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 14 ± 2 µM
dbacp03249 HAL-2/19 GKWMSLLKHWLK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 16 ± 4 µM
dbacp03252 HAL-2/2 GKWMKLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 1 µM
dbacp03255 HAL-2/20 GKWMSLWKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 30 ± 5 µM
dbacp03258 HAL-2/22 gkwmsllkhilk Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 µM
dbacp03261 HAL-2/24 GKFMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 34 µM
dbacp03264 HAL-2/4 GKWMSLLKKILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 40 µM
dbacp03267 HAL-2/6 GKWMSFLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 23 ± 3 µM
dbacp03270 HAL-2/8 GKWMSLLKHILK Sweat bees and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 3 µM
dbacp03305 HIV-TAT48-57 GRKKRRQRRR Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 7% apoptosis at 10 µM
dbacp03306 HIV-TAT48-57 GRKKRRQRRR Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 15% apoptosis at 20 µM
dbacp03307 HIV-TAT48-57 GRKKRRQRRR Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 35% apoptosis at 30 µM
dbacp03308 HIV-TAT48-57 GRKKRRQRRR Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 65% apoptosis at 50 µM
dbacp03525 KT2 NGVQPKYKWWKWWKKWW-NH2 Siamese freshwater crocodile leukocyte Inducing apoptosis Sulforhodamine B colorimetric assay CaSki Cervical cancer IC50 : 17.3 – 30.8 μM
dbacp03526 KT2 NGVQPKYKWWKWWKKWW-NH2 Siamese freshwater crocodile leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay CaSki Cervical cancer IC50 : 17.3 – 30.8 μM
dbacp03527 KT2 NGVQPKYKWWKWWKKWW-NH2 Siamese freshwater crocodile leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay CaSki Cervical cancer IC50 : 17.3 – 30.8 μM
dbacp03544 L-amino-acid oxidase ACTX-8 ADDRNPLEEFRENNYEEFL Venom base Inducing apoptosis MTT assay HeLa Cervical cancer MIC : 20 μg/ml
dbacp03545 L-amino-acid oxidase ACTX-8 (LAAO) (LAO) (EC 1.4.3.2) ADDRNPLEEFRENNYEEFL Hundred-pace Snake Inducing apoptosis MTT assay HeLa Cervical cancer MIC : 20 μg/ml
dbacp03577 L17A KWKSFLKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : > 83.6 µMo/L
dbacp03585 L17A/L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : >83.6 µMo/L
dbacp03596 L21A KWKSFLKTFKSAKKTVAHTAAKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 64.7 µMo/L
dbacp03620 L6A KWKSFAKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 58.6 µMo/L
dbacp03628 L6A/L17A KWKSFAKTFKSAKKTVAHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : >83.6 µMo/L
dbacp04180 LL-III VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 1 µM
dbacp04183 LL-III/1 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04186 LL-III/10 KNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 4 µM
dbacp04189 LL-III/11 VNWKKIILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 1 µM
dbacp04192 LL-III/12 vnwkkilgkiikvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 2 µM
dbacp04195 LL-III/15 VNFKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04198 LL-III/16 VN-NAl-KKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 6 ± 1 µM
dbacp04201 LL-III/17 VNWRRILGRIIRVVR Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 µM
dbacp04204 LL-III/18 KNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 µM
dbacp04207 LL-III/19 VNWKK-Aib-LGK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04210 LL-III/2 NVWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer Not found
dbacp04213 LL-III/22 KNWKK-Aib-LKK-Aib-IK-Aib-VK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 11 ± 7 µM
dbacp04216 LL-III/23 VNWKKLLGKLLKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 µM
dbacp04219 LL-III/24 VNWOOILGOIIOVVO Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04222 LL-III/25 vnwkkllgkllkvvk Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 4 ± 2 µM
dbacp04225 LL-III/26 VYWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 5 ±1 µM
dbacp04228 LL-III/27 VNWKKVLGKVVKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 13 ± 2 µM
dbacp04231 LL-III/3 VNWKKILKKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer Not found
dbacp04234 LL-III/34 NKWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 5 ± 2 µM
dbacp04237 LL-III/36 VNWKKILAKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 µM
dbacp04243 LL-III/4 VNWKKILGKIKKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04246 LL-III/6 VNWKKILPKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 40 µM
dbacp04249 LL-III/8 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 1 µM
dbacp04252 LL-III/9 VNWKKILGKIIKVVK Lasioglossin III and its analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 3 ± 1 µM
dbacp04317 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay HeLa Cervical cancer Not found
dbacp04321 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay EC109 Cervical cancer Not found
dbacp04325 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay HepG2 Cervical cancer Not found
dbacp04329 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay EJ Cervical cancer Not found
dbacp04333 LvHemB1 DVNFLLHKIYGNIRY Marine invertebrates Inducing apoptosis MTT assay THLE-3 Cervical cancer Not found
dbacp04376 MAC1 GFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 10 ± 4 µM
dbacp04379 MAC1/1 gfgmalkllkkvl Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 12 ± 4 µM
dbacp04382 MAC1/10 GFKMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 6 µM
dbacp04385 MAC1/16 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 32 ± 2 µM
dbacp04388 MAC1/19 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 21 ± 4 µM
dbacp04391 MAC1/2 AFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 16 ± 3 µM
dbacp04394 MAC1/20 GFGMALOLLOOVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 10 ± 1 µM
dbacp04397 MAC1/21 GFGMALRLLRRVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 3 µM
dbacp04400 MAC1/24 GFGMALKL-(AC6C)-KKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04403 MAC1/25 GFGMALK-(AC6C)-LKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 7 ± 1 µM
dbacp04406 MAC1/26 GFGMA-(AC6C)-KLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04409 MAC1/3 LFGMALKLLKKVL Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 9 ± 2 µM
dbacp04412 MAC1/4 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 15 ± 5 µM
dbacp04415 MAC1/6 GFGMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 2 µM
dbacp04418 MAC1/9 GFKMALKLLKKVL-NH2 Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : 8 ± 1 µM
dbacp04421 MAC2 GTGLPMSERRKIMLMMR Wallabies and their analogs Cell membrane damage MTT/MTS assay HeLa Cervical cancer IC50 : > 100 µM
dbacp04541 Malanin chain A DYPKLTFTTS Plant sources Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 0.15 ± 0.08 nM
dbacp04547 Malanin chain B DETCTDEEFN Plant sources Inducing apoptosis MTT assay HeLa Cervical cancer IC50 : 0.15 ± 0.08 nM
dbacp04592 Mauriporin MNKKTLLVIFFITMLIVDEVNSFKIGGFIKKLWRSKLAKKLRAKGRELLKDYANRVINGGPEEEAAVPAERRR Fat-tailed scorpion Induce cell apoptosis; Targets on the cell membranes and caused membrane lysis MTT assay, Lactate dehydrogenase (LDH) Release assay Hela Human cervical cancer IC50 : 27.9 μM - 283.3 μM
dbacp04677 MG2d GIGKFLHSAKKWGKAFVGQIMNC Synthetic Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90-100% viablity
dbacp05028 Peptide P KWKSFLKTFKSAKKTVLHTALKAISS PeptideV13K Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 10.4 µMo/L
dbacp05139 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 62 % Cytotoxicity at 50 mg/L
dbacp05140 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 44 % Cytotoxicity at 25 mg/L
dbacp05141 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05142 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 75 % Cytotoxicity at 50 mg/L
dbacp05143 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05144 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 3.125 mg/L
dbacp05145 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 78 % Cytotoxicity at 50 mg/L
dbacp05146 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 68 % Cytotoxicity at 25 mg/L
dbacp05147 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05148 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 6.25 mg/L
dbacp05149 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp05150 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp05151 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 80 % Cytotoxicity at 25 mg/L
dbacp05152 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 15 % Cytotoxicity at 12.5 mg/L
dbacp05153 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 12 % Cytotoxicity at 6.25 mg/L
dbacp05154 Pardaxin-1 GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp05175 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 50 mg/L
dbacp05176 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 60 % Cytotoxicity at 25 mg/L
dbacp05177 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 12.5 mg/L
dbacp05178 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 6.25 mg/L
dbacp05179 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 1 % Cytotoxicity at 3.125 mg/L
dbacp05180 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 78 % Cytotoxicity at 50 mg/L
dbacp05181 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05182 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 12.5 mg/L
dbacp05183 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 6.25 mg/L
dbacp05184 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 5 % Cytotoxicity at 3.125 mg/L
dbacp05185 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 82 % Cytotoxicity at 50 mg/L
dbacp05186 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 70 % Cytotoxicity at 25 mg/L
dbacp05187 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 12.5 mg/L
dbacp05188 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 4 % Cytotoxicity at 6.25 mg/L
dbacp05189 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 10 % Cytotoxicity at 3.125 mg/L
dbacp05190 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 90 % Cytotoxicity at 50 mg/L
dbacp05191 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 82 % Cytotoxicity at 25 mg/L
dbacp05192 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 12.5 mg/L
dbacp05193 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 6.25 mg/L
dbacp05194 Pardaxin-6 GFFALIPKIISSPLFKTLLSAVGSALS Brown-lined reefcod Inducing membrane permeabilization MTT/MTS assay HeLa Cervical cancer 18 % Cytotoxicity at 3.125 mg/L
dbacp05403 Peptide Glycyrrhetinic Acid Based Derivatives (compound 5) GGGG Not found Inducing apoptosis Not specified MCF-7 Cervical cancer IC50 : 5.0 ± 0.3 µg/mL
dbacp05404 Peptide Glycyrrhetinic Acid Based Derivatives (compound 5) GGGG Not found Inducing apoptosis Not specified HCT116 Cervical cancer IC50 : 5.2 ± 0.8 µg/mL
dbacp05405 Peptide K14D KWKSFLKTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.52 ± 0.05 µMol/L
dbacp05406 Peptide K14D/K22D KWKSFLKTFKSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.40 ± 0.09 µMol/L
dbacp05407 Peptide K1D/K3D/K7D /K10D/K14D/K22D kWkSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 18.07 ± 0.48 µMol/L
dbacp05408 Peptide K22D KWKSFLKTFKSLKKTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.39 ± 0.02 µMol/L
dbacp05409 Peptide K3D/K7D /K10D/K14D/K22D KWkSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 20.41 ± 0.64 µMol/L
dbacp05410 Peptide K7D KWKSFLkTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.29 ± 0.03 µMol/L
dbacp05411 Peptide K7D /K10D/K14D/K22D KWKSFLkTFkSLKkTVLHTLLkAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.79 ± 0.23 µMol/L
dbacp05412 Peptide K7D /K14D KWKSFLkTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.06 ± 0.01 µMol/L
dbacp05413 Peptide K7D /K14D/K22D KWKSFLkTFKSLKkTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 4.45 ± 0.19 µMol/L
dbacp05414 Peptide L12D KWKSFLKTFKSlKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.63 ± 0.07 µMol/L
dbacp05415 Peptide L12D/L20D KWKSFLKTFKSlKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.14 ± 0.06 µMol/L
dbacp05416 Peptide L20D KWKSFLKTFKSLKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.33 ± 0.06 µMol/L
dbacp05417 Peptide L6D KWKSFlKTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 2.23 ± 0.10 µMol/L
dbacp05418 Peptide L6D/L12D KWKSFlKTFKSlKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 3.01 ± 0.08 µMol/L
dbacp05419 Peptide L6D/L12D/L17D/L20D KWKSFlKTFKSlKKTVlHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 9.69 ± 0.38 µMol/L
dbacp05420 Peptide L6D/L12D/L17D/L20D/L21D KWKSFlKTFKSlKKTVlHTllKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 12.88 ± 0.15 µMol/L
dbacp05421 Peptide L6D/L12D/L20D KWKSFlKTFKSlKKTVLHTlLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 7.80 ± 0.26 µMol/L
dbacp05427 Peptide P KWKSFLKTFKSLKKTVLHTLLKAISS A12L/A20L Membrane disruption mechanism MTT/MTS assay HeLa Cervical cancer IC50 : 1.71 ± 0.07 µMol/L
dbacp05440 Peptide-20 CSSRTMHHC Synthetic Peptide Inducing apoptosis MTT/MTS assay HeLa Cervical cancer At 100 µM 50% viablity
dbacp05597 Polyphemusin III RRGCFRVCYRGFCFQRCR Atlantic horseshoe crab Induce permeabilization of the cytoplasmic membrane Trypan blue exclusion assay and Lactate dehydrogenase(LDH)-release assay HL-60 Human cervical cancer IC50 : < 10 μM
dbacp05743 PTPRJ-pep19 CHHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 4.5 ± 0.1.4% cell growth inhibition at 160 µM
dbacp05744 PTPRJ-pep19 CHHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 19 ± 2.82% cell growth inhibition at 160 µM
dbacp05745 PTPRJ-pep19.0 CHHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 4 ± 1.4% cell growth inhibition at 160 µM
dbacp05746 PTPRJ-pep19.2 CAHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 16.5 ± 2.12% cell growth inhibition at 160 µM
dbacp05747 PTPRJ-pep19.2 CAHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 30 ± 2.82% cell growth inhibition at 160 µM
dbacp05748 PTPRJ-pep19.2 CAHNLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 32.0 ± 4.2% cell growth inhibition at 160 µM
dbacp05749 PTPRJ-pep19.3 CHANLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 28 ± 5.5% cell growth inhibition at 160 µM
dbacp05750 PTPRJ-pep19.3 CHANLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 46 ± 4.2% cell growth inhibition at 160 µM
dbacp05751 PTPRJ-pep19.3 CHANLTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 51 ± 1.4% cell growth inhibition at 160 µM
dbacp05752 PTPRJ-pep19.4 CHHALTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 48.0 ± 2.82% cell growth inhibition at 160 µM
dbacp05753 PTPRJ-pep19.4 CHHALTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 62.5 ± 4.9% cell growth inhibition at 160 µM
dbacp05754 PTPRJ-pep19.4 CHHALTHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 66.5 ± 2.12% cell growth inhibition at 160 µM
dbacp05755 PTPRJ-pep19.5 CHHNATHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 2 ± 1.5% cell growth inhibition at 160 µM
dbacp05756 PTPRJ-pep19.5 CHHNATHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 19 ± 4.2% cell growth inhibition at 160 µM
dbacp05757 PTPRJ-pep19.6 CHHNLAHAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 19 ± 4.2% cell growth inhibition at 160 µM
dbacp05758 PTPRJ-pep19.7 CHHNLTAAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 4.5 ± 2.13% cell growth inhibition at 160 µM
dbacp05759 PTPRJ-pep19.7 CHHNLTAAC PTPRJ agonist peptides Cell growth inhibition and apoptosis Trypan blue assay HeLa Cervical cancer 20 ± 1.4% cell growth inhibition at 160 µM
dbacp05945 RGD-La RGDLLRHVVKILEKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 73.09 Inhibition ratio at 50 µg/ml
dbacp05954 RGD-Las RGDLLRHVVKILSKYL Arg-Gly-Asp(RGD) tripeptide ana temporins Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 78.045 Inhibition ratio at 50 µg/ml
dbacp05969 RGSALTHLP RGSALTHLP Siamese crocodile Leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay HeLa Cervical cancer IC50 : 126.24 ± 3.5 μM
dbacp05970 RGSALTHLP RGSALTHLP Siamese crocodile Leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay CaSki Cervical cancer IC50 : 168.33 ± 1.6 μM
dbacp05974 RP9 RGSALTHLP Siamese crocodile leukocyte extract Apoptosis Sulforhodamine B colorimetric assay, apoptosis array assay HeLa Cervical cancer IC50 : 126.2 μM
dbacp05975 RP9 RGSALTHLP Siamese crocodile leukocyte extract Apoptosis Sulforhodamine B colorimetric assay, apoptosis array assay CaSki Cervical cancer IC50 :168.3 μM
dbacp05981 RT2 NGVQPKYRWWRWWRRWW-NH2 Siamese crocodile leukocyte Inducing apoptosis Sulforhodamine B colorimetric assay HeLa Cervical cancer IC50 : 28.7–53.4 μM
dbacp05982 RT2 NGVQPKYRWWRWWRRWW-NH2 Siamese crocodile leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay HeLa Cervical cancer IC50 : 28.7–53.4 μM
dbacp05983 RT2 NGVQPKYRWWRWWRRWW-NH2 Siamese crocodile leukocyte Apoptosis inducing Sulforhodamine B colorimetric assay HeLa Cervical cancer IC50 : 28.7–53.4 μM
dbacp06035 Scolopin-2 ILKKFMLHRGTKVYKMRTLSKRSH Chinese red-headed centipede Regulate caspase-related apoptosis pathways MTT assay Hela Cervical cancer IC50 : 35 μM
dbacp06079 Short α-helical peptide GIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 99% Cytotoxicity at 4µM approx.
dbacp06080 Short α-helical peptide GIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 95 % Cytotoxicity at 4µM approx.
dbacp06081 Short α-helical peptide GIIKKIIKKIIKKIIKKI Alpha-helical proteins Cell membrane disruption; Cell apoptosis MTT/MTS assay HeLa Cervical cancer 80% Cytotoxicity at 4µM
dbacp06164 Stigmurin FFSLIPSLVGGLISAFK Venom gland, Yellow scorpion of the Northeast Cell membrane degradation MTT assay SiHa cells Cervical cancer IC50 : 118 μM
dbacp06196 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 1 µM 90 - 100% viablity
dbacp06197 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 10 µM 80% viablity
dbacp06198 Tat (47-57) YGRKKRRQRRR Synthetic construct Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer At 100 µM 60% viablity
dbacp06215 TAT-Ras-GAP317-326 GRKKRRQRRRGGWMWVTNLRTD Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 15% apoptosis at 10 µM
dbacp06216 TAT-Ras-GAP317-326 GRKKRRQRRRGGWMWVTNLRTD Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 47% apoptosis at 20 µM
dbacp06217 TAT-Ras-GAP317-326 GRKKRRQRRRGGWMWVTNLRTD Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 72% apoptosis at 30 µM
dbacp06218 TAT-Ras-GAP317-326 GRKKRRQRRRGGWMWVTNLRTD Not found Apoptosis inducing LDH leakage assay HeLa Cervical cancer 79% apoptosis at 50 µM
dbacp06250 Temporin-La LLRHVVKILEKYL Temporins family Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 52.32 inhibition ratio at 50 µg/ml
dbacp06259 Temporin-Las LLRHVVKILSKYL Temporins family Cell membrane disintegration MTT/MTS assay HeLa Cervical cancer 56.81 inhibition ratio at 50 µg/ml
dbacp06293 Tetramer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))4 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 0.96 nM
dbacp06346 Trimer of peptide-paclitaxel conjugate (K-Aib-C(CH2CO-2'-Pac))3 Synthetic peptide paclitaxel conjugate Not specified MTT/MTS assay HeLa Cervical cancer IC50 : 1.70 nM
dbacp06500 Vigno 5 GLPLCGETCVGGTCNTPGCSCGWPVCVRN Viola ignobilis Apoptosis inducing MTT assay, AO/EB and DAPI staining assay HeLa cells Cervical cancer IC50 : 2.5 – 10 μM
dbacp06501 Vigno 5 GLPLCGETCVGGTCNTPGCSCGWPVCVRN Viola ignobilis Apoptosis inducing MTT assay, AO/EB and DAPI staining assay L929 Cervical cancer IC50 : 2.5 – 10 μM
dbacp06639 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 64.15 µg/mL
dbacp06640 C-Mel CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 44.76 µg/mL
dbacp06642 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 67.34 µg/mL
dbacp06643 CM–FA CGIGAVLKVLTTGLPALISWIKRKRQQ Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.75 µg/mL
dbacp06645 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 50.72 µg/mL
dbacp06646 Mel-C GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 58.63 µg/mL
dbacp06648 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay HeLa Cervical Cancer IC50 = 66.43 µg/mL
dbacp06649 MC–FA GIGAVLKVLTTGLPALISWIKRKRQQC Synthetic analogue Plasma memberane pore formation MTT assay C-33A Cervical Cancer IC50 = 35.22 µg/ mL
dbacp06746 M1-20 grrrqrrkkrlgpfsidllikslsdnmtdl Synthetic Inhibits FOXM1 transcriptional activities CCK-8 assay HeLa Cervical Cancer IC50 = 42.95 µM
dbacp06765 M1-21 rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF Synthetic FOXM1 inhibitor Cell Viability assay HeLa Cervical Cancer IC50 = 31.83 µM
dbacp06793 CPSA-CPSC-L-ACAN Not Available Recombinant Fusion Peptide Apoptosis inducing MTT assay HeLa Cervical Cancer IC50 = 63.15 μg/ml
dbacp06805 [C/U, G1K, L5Y, K8R]cGm KURRYUYRQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 36.2 ± 2.8 μM
dbacp06811 [G1K, L5Y, K8R]cGm KCRRYCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 20.9 ± 1.4 μM
dbacp06817 [D-P L-P]cGm GCRRLCYKQRCVTYCRGpPR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 51.5 ± 3.9 μM
dbacp06821 [C/U]cGm GURRLUYKQRUVTYURGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06827 [G1K, K8R]cGm KCRRLCYRQRCVTYCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 44.2 ± 2.2μM
dbacp06833 [R4A, R18A]cGm GCRALCYKQRCVTYCRGA Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 > 64 μM
dbacp06839 [Y7W, K8R, Y14W]cGm GCRRLCWRQRCVTWCRGR Synthetic Analogue of Gomesin Cell membrane penetration Resazurin dye assay HeLa Cervical Cancer CC50 = 41.0 ± 4.2 μM
dbacp06851 WP1 RLLRLMRLRMLLRM Derived from RLL peptide Apoptosis inducing HDAC inhibition assay HeLa Cervical Cancer IC50 = 0.310±0.064 µM
dbacp06855 WP2 RLLRLLRLRRLLRL Derived from RLL peptide Apoptosis inducing HDAC inhibition assay HeLa Cervical Cancer IC50 = 0.446±0.095 µM
dbacp06861 LK-LE1 CLKKLLKLLKKLLKLCLHELLEHLHELLEH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 11.3 µM at pH 6
dbacp06862 LK-LE2 CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 12.9 µM at pH 6
dbacp06863 LK-LE3 CLKKLLKLLKKLLKLCLEELLHHLEELLHH Synthetic Membrane disruption MTT assay HeLa Cervical Cancer IC50 = 10.2 µM at pH 6
dbacp06911 mtp1 DGDWDAWTRETS Synthetic Disrupts transcription MTS assay HeLa Cervical Cancer 30.2 % decrease in cell viability at 10 μM
dbacp06976 C16-E4Y EEEEY Synthetic Inhibition of cell signalling WST-8 assay HeLa Cervical Cancer 60% cell viability at 0.05 wt %
dbacp07106 rScyreprocin MKEDSNILDKTAKMTKQNKALLFTAGGAAAFMAGYYYYHCNYRNPAPKKSGSTTSQDKTDAQAVQSIPSPSGNKGKESKDPKVKHHHHHH Recombinant product of Scyreprocin Membrane disruption triggers ROS-mediated apoptosis MTS assay HeLa Cervical cancer IC50 = 3.34 x 104 µM
dbacp07114 Galaxamide (N-Me-L)L(N-Me-L)LL Galaxaura filamentosa Cell-cycle arrest induces apoptosis MTT assay HeLa Cervical Cancer IC50 = 8.53 ± 0.73 µg/ml
dbacp07120 Z-1 L(N-Me-L)LPL Synthetic Cell-cycle arrest induces apoptosis MTT assay HeLa Cervical Cancer IC50 = 11.56 ± 0.65 µg/ml
dbacp07240 RB4 MADSERLSAPGCWAACTNFSRTRK Derived from protein PLP2 F-actin modulation induces necrotic death. MTT assay HeLa Cervical Cancer EC50 = 0.525 ± 0.160 mol/L × 10-3
dbacp07325 IK13 CIIKKIIKKIIKK Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 47±5 µM
dbacp07327 LK13 CLLKKLLKKLLKK Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 83 ± 9 µM
dbacp07329 IR13 CIIRRIIRRIIRR Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 > 100 µM
dbacp07331 LR13 CLLRRLLRRLLRR Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 26.7 ± 1.3 µM
dbacp07333 CI-15 CIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 2.7 ± 0.5 µM
dbacp07335 GI-15 LC-Propargyl-GIIKKIIKKIIKKII Synthetic Mitochondrial mediated apoptosis MTT assay HeLa Cervical Cancer IC50 = 16.6 ± 0.8 µM
dbacp07371 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay HeLa Cervical Cancer IC50 = 18.1 µM
dbacp07372 Piscidin 3 FIHHIFRGIVHAGRSIGRFLTG Morone chrysops x Morone saxatilis Cu²⁺-mediated membrane lipid oxidation MTT assay HeLa Cervical Cancer IC50 = 1.97 µM
dbacp07377 Brevinin-2DYd GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay HeLa Cervical Cancer IC50 = 19.69 µg/ml
dbacp07381 Ranatuerin-2Lb GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC Rana luteiventris Not Available MTT assay HeLa Cervical Cancer IC50 = 37.23 µM
dbacp07385 Odorranain-C1 GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC Odorrana grahami Not Available MTT assay HeLa Cervical Cancer IC50 = 52.83 µM
dbacp07389 Brevinin-2DYb GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC Rana dybowskii Not Available MTT assay HeLa Cervical Cancer IC50 = 23.26 µM
dbacp07393 Ranatuerin-2 GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP Rana catesbeiana Not Available MTT assay HeLa Cervical Cancer IC50 > 128 µM
dbacp07404 LvHemB1 DVNFLLHKIYGNIRY hemocyanin of Litopenaeus vannamei Mitochondrial targeting induces apoptosis MTS assay HeLa Cervical cancer 65.1% apoptotic cells at 50 μg/mL
dbacp07435 L9H5-1 LHLLLHLLHHLLHL Synthetic Acid-triggered membrane disruption apoptosis MTT assay HeLa Cervical Cancer IC50 = 5.4 µM
dbacp07436 L8H6 LHHLLHLLHHLLHL Synthetic Acid-triggered membrane disruption apoptosis MTT assay HeLa Cervical Cancer IC50 = 16.4 µM
dbacp07492 Figainin 1 FIGTLIPLALGALTKLFK Boana raniceps Membrane disruption, α-helix mediated MTT assay HeLa Cervical Cancer IC50 = 11.1 µM
dbacp07497 HX-12A FFRKVLKLIRKI Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 6.45 μM
dbacp07498 HX-12B FFRKVLKLIRKIF Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 7.61 μM
dbacp07499 HX-12C FFRKVLKLIRKIWR Synthetic derivative of Temporin-Pta ABCB1 inhibition, MDR reversal, sensitization MTT assay KB-C2 Cervical Cancer IC50 = 6.06 μM
dbacp07509 cyclic dipeptide - 2b WA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 93.1 µM
dbacp07809 cT1 KWCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 0.6 µM
dbacp07813 [R/K]cT1 KWCFKVCYKGICYKKCKG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 13.4 ± 1.9 µM
dbacp07819 [W2S]cT1 KSCFRVCYRGICYRRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 22.5 ± 2.1 µM
dbacp07829 [R14S]cT1 KWCFRVCYRGICYSRCRG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 7.5 ± 0.3 µM
dbacp07834 [R17S]cT1 KWCFRVCYRGICYRRCSG Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 12.2 ± 0.4 µM
dbacp07842 [G18K]cT1 KWCFRVCYRGICYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 6.7 ± 1.1 µM
dbacp07847 [I11F-G18K]cT1 KWCFRVCYRGFCYRRCRK Synthetic Not Available Resazurin dye assay HeLa Cervical Cancer CC50 = 5.1 ± 0.3 µM
dbacp07925 oligopeptide 1 AGAPGG Sarcophyton glaucum Selective cytotoxicity, DNA damage, apoptosis MTT assay HeLa Cervical Cancer EC50 = 8.6 mmol/L
dbacp07928 B11 RIRDAIAHGYIVDKV Litopenaeus vannamei hemocyanin-derived peptide Mitochondrial dysfunction, caspase-dependent apoptosis MTS assay HeLa Cervical Cancer Decreased cell viability by 20% at 50 μg/mL
dbacp07943 TC22 MTVVLLLIVLPLLGGVHSSGIL Tribolium castaneum ROS, p53, mitochondrial apoptosis activation MTT assay HeLa Cervical Cancer Fig 4a
dbacp07946 Emericellipsin A (3-MeP)-(AHMOD)-A-Aib-IV-beta-A-N-(2-Hydroxyethyl)-1,2-propanediamine Emericellopsis alkalina Membrane disruption, antifungal, antibacterial, anticancer MTT assay HeLa Cervical Cancer EC50 < 0.5 uM
dbacp07994 [G10a]SHa FLSGIVGMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 = 22.7 ± 0.86 µM
dbacp07997 [G10a]SHa-BCTP FLSGIVGMLaKLFLFKQYAELW Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08000 [G4a]SHa FLSaIVGMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08003 [G7a]SHa FLSGIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08006 [G4,7a]SHa FLSaIVaMLGKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08009 [G4,7,10a]SHa FLSaIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08012 [G7,10a]SHa FLSGIVaMLaKLF Synthetic analogue of Temporin-1SHa Enhanced cationicity/hydrophobicity increases cytotoxicity MTT assay HeLa Cervical Cancer IC50 >100 µM
dbacp08087 PTP-7S EENFLGALFKALSKLL PTP-7 Not Available MTT assay HeLa Cervical Cancer 55 - 60% cell viability at 75 µM
dbacp08113 FR-15 FRRFFKWFRRFFKFF Synthetic Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 4.9 μM
dbacp08117 FR4P FRRPFKWFRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 7.7 μM
dbacp08121 FR8P FRRFFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 10.5 μM
dbacp08125 FR11P FRRFFKWFRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 11 μM
dbacp08129 FR4,8P FRRPFKWPRRFFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 13.8 μM
dbacp08133 FR8,11P FRRFFKWPRRPFKFF Analogue of FR-15 Proline-substituted AMP triggers mitochondrial apoptosis MTT assay HeLa Cervical Cancer IC50 = 18.9 μM
dbacp08140 Laterosporulin10 (LS10) ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL Brevibacillus sp. strain SKDU10 Apoptosis inducing MTT assay HeLa Cervical Cancer 20% cytotoxicity 5 μM concentration
dbacp08141 Laterosporulin10 (LS10) ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL Brevibacillus sp. strain SKDU10 Apoptosis inducing LDH leakage assay HeLa Cervical Cancer ~80% LDH release at 15 μM
dbacp08151 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 40% LDH release at 32 μM
dbacp08152 IL-1 FKAGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 73.9 ± 13.6 μM
dbacp08154 IL-1 FKAGGFIKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 30% LDH release at 32 μM
dbacp08155 IL-2 FKIGGFAKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 52.0 ± 5.8 μM
dbacp08157 IL-2 FKIGGFAKKLWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 30% LDH release at 32 μM
dbacp08158 IL-3 FKIGGFIKKAWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 93.5 ± 19.4 μM
dbacp08160 IL-3 FKIGGFIKKAWRSLLA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 35% LDH release at 32 μM
dbacp08161 IL-4 FKIGGFIKKLWRSALA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 54.4 ± 3.0 μM
dbacp08163 IL-4 FKIGGFIKKLWRSALA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 28% LDH release at 32 μM
dbacp08164 IL-5 FKIGGFIKKLWRSLAA Synthetic Ile/Leu residues crucially mediate cytolysis MTT assay HeLa Cervical Cancer IC50 = 28.0 ± 4.6 μM
dbacp08166 IL-5 FKIGGFIKKLWRSLAA Synthetic Ile/Leu residues crucially mediate cytolysis LDH leakage assay HeLa Cervical Cancer 35% LDH release at 32 μM
dbacp08266 ZXR-2 FKIGGFIKKLWRSLLA Synthetic Not Available MTT assay HeLa Cervical Cancer IC50 = 8.1 ± 1.6 μM
dbacp08273 [Lys5,6] TG UGLUKKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 10 µM
dbacp08275 [Lys6] TG UGLUGKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 2 µM
dbacp08277 Trichogin GA UGLUGGLUGI Trichoderma longibrachiatum Not Available MTT assay HeLa Cervical Cancer EC50 = 8 µM
dbacp08279 [TOAC1] TG XGLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 3 µM
dbacp08281 [TOAC1, Lys6] TG XGLUGKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 3 µM
dbacp08283 [Arg2] TG URLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 4 µM
dbacp08285 [TOAC1, Arg2] TG XRLUGGLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 9 µM
dbacp08287 [TOAC1, Arg9] TG XGLUGGLURI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 5 µM
dbacp08289 [TOAC1, Lys5,6] TG XGLUKKLUGI Trichogin GA Not Available MTT assay HeLa Cervical Cancer EC50 = 6 µM
dbacp08344 Phakellistatin 18 PIPYPIF Marine Sponge Phakellia fusca Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 = 82.25 µM
dbacp08346 P18-1 PIPYPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 = 41.28 µM
dbacp08348 P18-2 PIPRPIF Analogue of Phakellistatin 18 Not Available Cytotoxicity assay BEL-7042 Cervical Cancer IC50 >100 µM